Harbour BioMed inks agreement for ‘next generation biologic discovery’

By Maggie Lynch

- Last updated on GMT

(Image: Getty/ anusorn nakdee)
(Image: Getty/ anusorn nakdee)

Related tags Biologics Drug discovery Immunology Immunotherapy Drug development Drug development process

Harbour BioMed and an unnamed ‘leader’ in immunology enter license agreement to develop, discover, and commercialize biologic therapeutics using the former’s transgenic mouse platform.

Harbour BioMed’s platform for heavy chain only antibodies (HCAbs) generates fully human heavy chain antibodies to be used to accelerate the discovery and development of biologic therapeutics. 

Jinhson Wang, CEO of Harbour BioMed said in a statement, “Drug discovery in the burgeoning fields of immuno-oncology and immunotherapy is relying increasingly on advanced biological approaches to selectively attack one or more immune targets and modulate the immune system to treat cancer and other diseases.”

Harbour has used its HCAb platform in other discovery and development programs to create alternatives for domain antibodies, bi-specific and multi-specific antibodies, and chimeric antigen receptor (CAR) T-cell therapies.

“The HCAb platform is emerging as a powerful technology to enable next generation biologic discovery for our internal portfolio and a select group of licensing partners,”​ Wang further explained.

While Harbour has not released the name of its licensing partner, it did state that the company was a global pharmaceutical organization specializing in immunology and immune-oncology.

Through this agreement, Harbour will receive an undisclosed upfront payment and will be eligible to receive further development and sales related milestone payments and royalties.

In June of 2018 WuXi Biologics and Harbour entered an agreement​ with WuXi Biologics to develop and manufacture ‘heavy chain only’ antibodies. Per that deal, WuXi provided services to supply Harbour’s products for clinical trials.

Related news

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us


View more